Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Bases de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Emerg Infect Dis ; 27(3): 862-871, 2021 03.
Artigo em Inglês | MEDLINE | ID: mdl-33622477

RESUMO

Pertussis is a vaccine-preventable disease, and its recent resurgence might be attributable to the emergence of strains that differ genetically from the vaccine strain. We describe a novel pertussis isolate-based surveillance system and a core genome multilocus sequence typing scheme to assess Bordetella pertussis genetic variability and investigate the increased incidence of pertussis in Austria. During 2018-2020, we obtained 123 B. pertussis isolates and typed them with the new scheme (2,983 targets and preliminary cluster threshold of <6 alleles). B. pertussis isolates in Austria differed genetically from the vaccine strain, both in their core genomes and in their vaccine antigen genes; 31.7% of the isolates were pertactin-deficient. We detected 8 clusters, 1 of them with pertactin-deficient isolates and possibly part of a local outbreak. National expansion of the isolate-based surveillance system is needed to implement pertussis-control strategies.


Assuntos
Bordetella pertussis , Coqueluche , Alelos , Áustria , Proteínas da Membrana Bacteriana Externa/genética , Bordetella pertussis/genética , Humanos , Vacina contra Coqueluche , Fatores de Virulência de Bordetella
2.
Antimicrob Agents Chemother ; 54(9): 4006-8, 2010 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-20585127

RESUMO

An increase in extended-spectrum-beta-lactamase (ESBL)-producing Escherichia coli has been observed in outpatient settings. Consequently, 100 ESBL-positive E. coli isolates from ambulatory patients with clinically confirmed urinary tract infections were collected by a single laboratory between October 2004 and January 2008. Antimicrobial susceptibility testing was carried out using the oral antibiotics fosfomycin, pivmecillinam, and nitrofurantoin and the parenteral antibiotic ertapenem. Susceptibility rates indicate that fosfomycin (97%), nitrofurantoin (94%), and pivmecillinam (85%) could be considered important oral treatment options.


Assuntos
Escherichia coli/efeitos dos fármacos , Escherichia coli/patogenicidade , Infecções Urinárias/microbiologia , beta-Lactamases/metabolismo , Andinocilina Pivoxil/farmacologia , Andinocilina Pivoxil/uso terapêutico , Antibacterianos/farmacologia , Antibacterianos/uso terapêutico , Escherichia coli/enzimologia , Infecções por Escherichia coli/tratamento farmacológico , Infecções por Escherichia coli/microbiologia , Fosfomicina/farmacologia , Fosfomicina/uso terapêutico , Humanos , Testes de Sensibilidade Microbiana , Nitrofurantoína/farmacologia , Nitrofurantoína/uso terapêutico , Infecções Urinárias/tratamento farmacológico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA